<GlossaryTerm id="CDR0000579644"><TermName>canertinib dihydrochloride</TermName><TermPronunciation>(can-ER-tih-nib dy-HY-droh-KLOR-ide)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of some types of cancer. Canertinib dihydrochloride blocks the action of proteins called epidermal growth factor receptors, and may cause cancer cells to die. It is a type of tyrosine kinase inhibitor. Also called CI-1033.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000720460" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;canertinib dihydrochloride&quot;" language="en" id="_3"/><MediaLink ref="CDR0000720461" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;diclorhidrato de canertinib&quot;" language="es" id="_4"/><SpanishTermName>diclorhidrato de canertinib</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de algunos tipos de cáncer. El diclorhidrato de canertinib bloquea la acción de las proteínas llamadas receptores del factor de crecimiento epidérmico y es posible que destruya células cancerosas. Es un tipo de inhibidor de tirosina–cinasas. También se llama CI-1033.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2007-11-30</DateFirstPublished><DateLastModified>2008-01-09</DateLastModified></GlossaryTerm>
